Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study to Evaluate the Microbiome as a Biomarker of Efficacy and Toxicity in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy

NCT04107168 is registered in ClinicalTrials.gov with CCTU- Cancer Theme as lead sponsor.

NCT NCT04107168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04107168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study to Evaluate the Microbiome as a Biomarker of Efficacy and Toxicity in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy
Lead sponsor
CCTU- Cancer Theme
Phase
Observational
Overall status
Unknown status
Start date
July 8, 2020
Completion date
July 8, 2025
Enrollment
1,800 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, melanoma, renal cancer